Open AccessThe resolution on empagliflozin and heart failure has been adopted by the experts of the Siberian Federal District based on the results of the EMPEROR-Reduced study
Author(s) -
О. Л. Барбараш,
А. А. Гарганеева,
Н. Г. Гоголашвили,
А. А. Ефремушкина,
S. L. Zharskiy,
В. В. Кашталап,
О. Yu. Korennova,
С. А. Макаров,
В. А. Невзорова,
К. В. Протасов,
S. A. Ustyugov,
O. Yu. Shabelnikova
Publication year - 2021
Publication title -
kompleksnye problemy serdečno-sosudistyh zabolevanij
Language(s) - English
Resource type - Journals
eISSN - 2587-9537
pISSN - 2306-1278
DOI - 10.17802/2306-1278-2021-10-1-103-108
Subject(s) - empagliflozin , emperor , medicine , heart failure , history , ancient history , endocrinology , diabetes mellitus , type 2 diabetes mellitus
The results of the international multicenter study EMPEROR-Reduced have been discussed on October 31, 2020, at the online expert meeting. Considering the positive cardiovascular and renal effects of empagliflozin, the experts have supported the use of empagliflozin in the clinical practice to treat patients with chronic heart failure.